Effect of Oral Atorvastatin on CD4+CD25+ Regulatory T Cells, FoxP3 Expression, and Prognosis in Patients With ST-Segment Elevated Myocardial Infarction Before Primary Percutaneous Coronary Intervention

Primary percutaneous coronary intervention: different outcome for different subgroups?

(2010) Stefano Savonitto et al.   Journal of Cardiovascular Medicine

High-risk non-ST-segment elevation myocardial infarction versus ST-segment elevation myocardial infarction: same behaviour and outcome?

(2010) Antonio Manari et al.   Journal of Cardiovascular Medicine

ST Elevation Myocardial Infarction Guidelines Today: A Systematic Review Exploring Updated ACC/AHA STEMI Guidelines and Their Applications

(2009) Rohit Seth Loomba et al.   AMERICAN JOURNAL OF THERAPEUTICS

Atherosclerotic plaque development

(2009) Quang T. Bui et al.   INTERNATIONAL JOURNAL OF BIOCHEMISTRY & CELL BIOLOGY

Comparison of Benefits and Risks of Rosuvastatin Versus Atorvastatin from a Meta-Analysis of Head-to-Head Randomized Controlled Trials

(2008) John Wlodarczyk et al.   AMERICAN JOURNAL OF CARDIOLOGY

2007 Focused Update to the ACC/AHA Guidelines for the Management of Patients With ST-Segment Elevation Myocardial Infarction: Implications for Emergency Department Practice

(2008) Charles V. Pollack et al.   ANNALS OF EMERGENCY MEDICINE

Anti tumour necrosis-α therapy increases the number of FOXP3+regulatory T cells in children affected by Crohn’s disease

(2008) Ida Ricciardelli et al.   IMMUNOLOGY

The role of cytokine in regulation of the natural killer cell activity

(2008) Vladimir Jurisic et al.   Srpski Arhiv za Celokupno Lekarstvo